Kelsh, R.M., Mckeown-Longo, P.J. and Clark, R.A.F.: EDA Fibronectin
Total Page：16
File Type：pdf, Size：1020Kb
COMMENTARY Gauthier Y, Cario-Andre M, Lepreux S et al. (2003) Clinical Implications Melanocyte detachment after skin friction in ● In vitiligo, all the skin is affected. non lesional skin of patients with generalized vitiligo. Br J Dermatol 148:95–101 ● fi Modi cation of pigment distributions in the skin may be associated with Haass NK, Herlyn M (2005) Normal human melanocyte other alterations, such as defects in the epidermal barrier. homeostasis as a paradigm for understanding mela- noma. J Invest Dermatol Symp Proc 10:153–63 ● Stabilization of the disease, by targeting nonlesional skin, is an additional challenge for improving the benefits of treatment. Harris JE, Harris TH, Weninger W et al. (2012) A mouse model of vitiligo with focused epider- ● Full-body phototherapy may stabilize the disease by inducing the differentia- mal depigmentation requires IFN-γ for auto- + tion of melanocytes, with consequent improvements in cell–cell adhesion. reactive CD8 T-cell accumulation in the skin. JInvestDermatol132:1869–76 ● Counteracting extracellular and intracellular oxidative stress may con- Jin Y, Birlea SA, Fain PR et al. (2012) Genome-wide tribute to reducing melanocyte detachment and disease progression. association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet 44:676–80 Kovacs D, Abdel-Raouf H, Al-Khayyat M et al. (2015) Vitiligo: characterization of melano- Cario-André M, Pain C, Gauthier Y et al. (2007) The Recently, immunohistochemical examina- cytes in repigmented skin after punch grafting. melanocytorrhagic hypothesis of vitiligo tested tion of E-cadherin in tissue sam- J Eur Acad Dermatol Venereol 29:581–90 on pigmented, stressed, reconstructed epider- ples collected from patients with vitiligo, mis. Pigment Cell Res 20:385–93 Richmond JM, Frisoli ML, Harris JE (2013) Innate after punch grafting, revealed that melano- immune mechanisms in vitiligo: danger Dell’Anna ML, Picardo M (2006) A review and a from within. Curr Opin Immunol 25:676–82 cytes from normally pigmented donor new hypothesis for non-immunological patho- sites may migrate toward lesional skin genic mechanisms in vitiligo. Pigment Cell Res Schallreuter KU, Salem MA, Gibbons NC et al. (2012) 19:406–11 Blunted epidermal L-tryptophan metabolism in and repopulate the depigmented areas vitiligo affects immune response and ROS because of decreased E-cadherin expres- Denat L, Kadekaro AL, Marrot L et al. (2014) scavenging by Fenton chemistry, part 2: Epider- sion (Kovacs et al., 2015). The mecha- Melanocytes as instigators and victims of mal H2O2/ONOO( − ) − mediated stress in viti- oxidative stress. JInvestDermatol134:1512–8 nisms that underly the activation of ligo hampers indoleamine 2,3-dioxygenase and Eleftheriadou V, Thomas K, van Geel N et al. (2015) aryl hydrocarbon receptor-mediated immune melanocytes after punch grafting have not Developing core outcome set for vitiligo response signaling. FASEB J 26:2471–85 been fully explained. Nevertheless, the clinical trials: international e-Delphi consen- Wagner RY, Luciani F, Cario-Andre M et al. (2015) process might be regulated by epidermal sus. Pigment Cell Melanoma Res Altered E-cadherin levels and distribution in and dermal cells that should be able to Ezzedine K, Eleftheriadou V, Whitton M et al. melanocytes precedes manifestations of vitiligo. – manage cell adhesion actively. (2015) Vitiligo. Lancet J Invest Dermatol 135:1810 20 + Therapeutic options for vitiligo are still Ezzedine K, Lim HW, Suzuki T et al. (2012) Revised Wu J, Zhou M, Wan Y et al. (2013) CD8 T cells classification/nomenclature of vitiligo and related from vitiligo perilesional margins induce auto- limited. Although some mechanisms under- issues: the Vitiligo Global Issues Consensus Con- logous melanocyte apoptosis. Mol Med Rep 7: lying the interplay between oxidative stress ference. Pigment Cell Melanoma Res 25:E1–13 237–41 and immunity have been postulated (Richmond et al., 2013), understanding See related letter to the editor on pg 1921 mechanisms that cause oxidative stress could provide valuable information to identify new therapeutic targets. The chal- lenge will be to maintain cells metabo- EDA Fibronectin in Keloids Create a lically active as requirement for sustaining the energy demand and coping with oxida- Vicious Cycle of Fibrotic Tumor Formation tive stress. Moreover, the analysis has to be 1 1 2 extended to pigmented skin to both identify Rhiannon M. Kelsh , Paula J. McKeown-Longo and Richard A.F. Clark early events in “silent” vitiligo melanocytes During the early phase of wound healing, first plasma fibronectin (FN) and then in situ and prevent the spread of the disease. FN are deposited at the site of injury. In situ FN––FN made by tissue cells at the injury –– CONFLICT OF INTEREST site oftencontainsanextradomainA(EDA)insert. Multiple wound-related signal The authors state no conflict of interest. transduction pathways control the deposition of EDA FN, and the EDA insert can in turn trigger pathways that induce inflammation, increased extracellular matrix REFERENCES molecule deposition including FN and collagen, and activation of fibroblasts. Together Ardigo M, Malizewsky I, Dell’Anna ML et al. (2007) these pathways can create a vicious cycle that leads to fibrosis or keloid formation. Preliminary evaluation of vitiligo using in vivo Journal of Investigative Dermatology (2015) 135, 1714–1718. doi:10.1038/jid.2015.155 reflectance confocal microscopy. J Eur Acad Dermatol Venereol 21:1344–50 Bellei B, Pitisci A, Ottaviani M et al. (2013) Vitiligo: 1Center for Cell Biology & Cancer Research, Albany Medical College, Albany, New York, USA and a possible model of degenerative diseases. 2Departments of Dermatology and Biomedical Engineering, Stony Brook University, Stony Brook, New York, PLoS One 8:e59782 USA Bertolotti A, Boniface K, Vergier B et al. (2014) Correspondence: Paula J. McKeown-Longo, Center for Cell Biology & Cancer Research, Mail Code 165, Type I interferon signature in the initiation of Albany Medical College, 47 New Scotland Avenue, Albany, New York 12208, USA or Richard A.F. Clark, the immune response in vitiligo. Pigment Cell Departments of Dermatology and Biomedical Engineering, Stony Brook University, HSC T-16, 060, Stony Melanoma Res 27:398–407 Brook, New York 11794-8165, USA. E-mail: [email protected] or [email protected] 1714 Journal of Investigative Dermatology (2015), Volume 135 COMMENTARY FN is an extracellular matrix (ECM) EDA glycoprotein critical for embryogenesis, EDB morphogenesis, and wound repair (Clark, fi 2014). Although plasma bronectin (FN), NH CH which is synthesized by the liver, v circulates in blood as non-complexed SS molecules in a 1:10 ratio with fibrinogen SS (Greiling and Clark, 1997), little FN ECM NH CH exists in fully developed tissue (Yamada and Clark, 1996). However, tissue injury EDB or inflammation leads to rapid plasma FN EDA deposition in complex with fibrin followed by so-called cell FN deposition by tissue cells a few days later (Yamada Alternatively spliced Fn I Fn II Fn III Variable region and Clark, 1996). Plasma FN exists as Fn III v 250 kDa glycoprotein consisting of two fi fi chains, one with and one without a Figure 1. Depiction of the modular structure of bronectin. Plasma bronectin consists of two chains, made up of repeating, modular structures: type I (blue), type II (green), and type III (yellow). One chain variable domain (v). Although cell FN contains the variable region (purple) and the other does not. Alternative splicing of the gene results in the comes from the same gene as plasma FN, synthesis of fibronectin that contains the extra domains A (EDA) and B (EDB; pink). it contains additional spliced variants with extra domains A and/or B (EDA and/or EDB; Figure 1). Both plasma and circumstances of tissue remodeling, such mTOR signaling pathway facilitates cell FN are polymerized into fibrils and as during wound repair, tissue injury, phosphorylation and activation of the deposited into the ECM of most tissues. inflammation, and fibrosis (ffrench- splicing factor SF2/ASF (also known Most of the secondary structure of FN is Constant et al., 1989; Peters et al., as SRSF1), resulting in the increased organized into individually folded 1989; Satoi et al., 2000; Singh et al., expression of EDA FN. It was proposed domains based on amino acid homology 2004; Muro et al., 2008). The mecha- that the modulation of AKT activity was (Petersen et al., 1983). These domains, nisms that trigger upregulation of the EDA a direct result of TGF-β-induced termed Type I, II, and III, also represent FN isoform are both cell type specificand downregulation of PTEN (White et al., biologically sites that participate in the context dependent, making it critical to 2010). These studies suggest that TGF-β formation of matrix fibrils and provide understand the regulation of this process family members can control EDA levels binding sites for cells, other matrix mole- in response to extracellular signals. The by altering activity and/or expression cules, and growth factors (Schwarzbauer molecular mechanism controlling alter- levels of splicing factors. and DeSimone, 2011; Zhu and Clark, native mRNA splicing of the EDA exon In addition to TGF-β, growth factors, 2014). As FN is extremely sensitive to depends on spliceosome assembly and such as HGF and EGF, as well as stress proteolysis, FN must be deposited RNA secondary structure, as well as the signals, have been implicated in regulat- continuously from blood or from in situ serine/arginine (SR)-rich family of proteins ing increased levels of EDA FN (Inoue tissue cell production to sustain its pre- (Lavigueur et al., 1993; Mermoud et al., et al., 1999). Interestingly, it is known sence (Deno et al., 1983). With healing of 1994 Cramer et al., 1997; Buratti and that HGF works through the PI3K a wound or resolution of inflammation, Baralle, 2004). Growth factors, stress cascade to increase levels of EDA FN both plasma FN and cell FN disappear signals, ECM proteins, cytokines, and (Magnuson et al., 1991; Seebacher et al., rapidly from the tissue (Welch et al., 1990).